From opening Nap Bar and consulting corporations on diversity and inclusion to serving the city as an LGBT adviser, Khaliah Guillory is focused on productivity. Courtesy of Khaliah Guillory

Khaliah Guillory is an avid napper — and she's had to be. A multiple hat wearer and big proponent of side hustles, she's always piled responsibilities high on her plate.

Earlier this year left a corporate leadership position to open Nap Bar in Rice Village, but for years before that, she had her diversity and inclusion side hustle, KOG & Company. She works with companies — big and small — to integrate the best diversity and inclusion initiatives into the workplace.

"The intersection between KOG and Nap Bar and the common denominator is productivity and performance," Guillory says. "From a corporate standpoint — even when you think about diversity and inclusion — it all boils down to we want people who don't look like us or don't come from where we come from to be productive and perform well."

Guillory, who is this week's Pride Month Featured Innovator on InnovationMap, also serves on Mayor Sylvester Turner's LGBT Advisory Board.

InnovationMap: When did you know you wanted to be an entrepreneur?

Khaliah Guillory: I was 8 or 9 years old, and my family drank a lot of soda. Where I grew up in Port Arthur, Texas, you could go and trade in cans for change. I would go outside, line up all the cans, and step on them to crush them. I saw an infomercial about a can crusher. It made my business more efficient. That's when my entrepreneurial journey started.

IM: How did The Nap Bar come about? 

KG: I have always been an avid napper. When I was in Kindergarten, and the teacher would say go grab your red or blue mat, I did it and I was out. I enjoyed naptime. In high school, I played basketball and I napped at the end of school. When I got into college, I played basketball at the University of Central Florida. My days would start at 5 am and wouldn't end until midnight. The only way I was able to graduate on time and maintain my grades for my scholarships was napping. It just continued throughout my professional career, and I started napping in my car.

One day, my wife and I commuted into the city — we live in the Sugar Land/Richmond area. We had about an hour and a half to spare. It was nap time, but it would be awkward with her in the car. She suggested Googling naps in Houston. She says, "We live in Houston, there's got to be a place where you could take a quick nap." There was no such place. She told me I should create it. That was April of last year.

IM: Then what did you do to get the ball rolling?

KG: The next day I surveyed all my friends and asked them if I was the only one out here napping. I quickly realized that I wasn't. Specifically, 52 percent of Americans, according to Amerisleep, admitted to napping at work. I committed to doing more research. I've committed 10,000 plus hours to researching the benefits to napping and the indicators of sleep exhaustion. Fast forward to November of last year, I transitioned away from my C-level position at a Fortune 500 company to really pursue Nap Bar.

IM: How’s business been?

KG: We just celebrated our 30th day of business a couple of weeks ago. We are already generating revenue. We are excited for what's to come. June is shaping up to be a real opportunity for us to be in the black, and July is shaping up to have a lot of events. We found that our biggest challenge is educating the masses on the benefits of taking a chill session in the middle of the day, and also educating on the indicators of what it's like to be sleep deprived.

IM: With KOG & Company, your other company, you’ve worked for years with large companies to help incorporate diversity and inclusion. How does that tie into your nap research?

KG: The intersection between KOG and Nap Bar and the common denominator is productivity and performance. From a corporate standpoint — even when you think about diversity and inclusion — it all boils down to we want people who don't look like us or don't come from where we come from to be productive and perform well. The best place for any corporation that has a philosophy or a vision of values and embraces corporate social responsibility is to acknowledge that people are going to be the heartbeat of their company.

IM: What do organizations — from startups to Fortune 500 companies — need to know about diversity and inclusion?

KG: The biggest thing is that from a culture standpoint, just simply hiring people to check a box isn't going to provide the desired ROI. It really, truly has to be embraced by the culture. If I am a business owner or corporation, and my goal is to have a diversity of talent, then I need to go where those people are. If I create and curate an environment with diversity and inclusivity, then going to recruit and then ask them what type of organization they want to work for and what it would look like — then go out and build that. And if they don't know where to start, they can hire me and I can hold their hand and give some real life experience. I've lived it as a banker, as a supervisor, and as a C-level executive.

IM: What’s surprised you about being on Mayor Sylvester Turner’s LGBT Advisory Board?

KG: I think what surprised me most about is that the city of Houston is really progressing and striving. It just makes sense. We're the most diverse city in the country, and I applaud Mayor Sylvester Turner for assembling the LGBT Advisory Board and for appointing me.

The city of Houston — and all the entities that fall under it from a government landscape — is desiring a journey to get more training and education. How do we educate on how to report a hate crime. How do we make sure that city employees are showing up to work and are 100 percent comfortable in their own skin. The biggest surprise I'd have to say is that the city has done an incredible job with the training. I walked away from the meeting learning things that I didn't even know about the LGBTQ community.

IM: What does Pride Month mean to you?

KG: Pride means to me being comfortable in my skin as I am, who I am. The month is a pleasant reminder to be "me" every day, all day. Pride month means my uniqueness is celebrated, not tolerated which should be the norm everyday; not just a month. Pride means being secure in the community — workplace, networking event, the gym, basically everywhere — and confidently say "my wife."

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.